Hyderabad: Pharmaceutical major Bharat Biotech on Wednesday said its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials.
The study has been accepted and published in Nature Scientific Reports, a high impact factor journal.
A press release from the vaccine maker said the study was conducted in 184 subjects, who were randomised 1:1 and received either a booster dose of Covaxin or a placebo, six months after the primary series of two doses.
Subjects were evaluated for safety, neutralising antibody responses against variants of concern, binding antibodies against spike protein, RBD, N proteins, and for memory T and B cell responses to demonstrate cell-mediated immunity, it said.
Krishna Ella, chairman and managing director, Bharat Biotech, said the team has now demonstrated that Covaxin is a multi-epitope vaccine with antibodies against spike, RBD and N proteins.
“Post booster dose, it has proven neutralising antibody responses against variants of concern and long term protection through memory T and B cell responses. We have now achieved our goal of developing a safe and efficacious vaccine with long-term protection against a spectrum of variants,” Ella said.
Covaxin, is formulated uniquely such that the same dosage can be administered to adults and children alike, for primary and booster doses, making it truly a universal vaccine, the company release said.
The jab is a ready-to-use liquid vaccine, stored at 2-8 degrees Celsius, with 12-months shelf life and multi-dose vial policy.
Bharat Biotech has a stockpile of more than 50 million doses of Covaxin ready to be distributed as and when required.
Also Read | SC grants bail to Alt News co-founder Mohd Zubair in all UP FIRs
- India to unveil new Foreign Trade Policy 2023-28
- Former civil servants condemn Rijiju’s remarks on judiciary in open letter
- FSSAI allows labelling curd in regional names amid controversy
- Meghalaya: Asian leopard cat rescued by GHADC forest officials
- IOC asks IOA to appoint CEO without further delay
- Assam: Rabha Unions’ demand CBI probe into death of BSF constable